Tripos Discovery Research, a Subsidiary of Commonwealth Biotechnologies, Announces Collaboration with Schering-Plough for Design and Synthesis of Novel Compounds
2007 NOV 19 -- Tripos Discovery Research Limited (TDR), a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. (CBI) group of companies (NASDAQ Capital Market:CBTE) and a leading provider of drug discovery chemistry services and small molecule products, announces that it has entered into a service agreement with Schering-Plough Corporation (NYSE:SGP) to design, synthesize and purify high-quality, drug-like compounds to expand the compound file collection of Schering-Plough Research Institute (SPRI), the company's research and development arm. Under the terms of this agreement, TDR will utilize its industry-leading proprietary design software ChemSpace(R) to collaborate with SPRI in the design of high-quality compound libraries as well as large-scale, high-throughput synthesis, purification and analysis of the compounds. Mark Warne, Managing Director of Tripos Discovery Research stated that "SPRI's file enhancement initiative is ideally suited to TDR's capabilities. Our expertise and proprietary software for innovative design of high quality libraries, as well as proven success for timely delivery, has helped us forge and sustain important value-added partnerships with our customers. We are delighted that SPRI has joined a long list of pharmaceutical and biotechnology clients which have partnered with TDR for the design and synthesis of high quality focused and diverse compound libraries." Keywords: Biotechnology Business, Biotechnology Company, Commonwealth Biotechnologies Inc., Drug Development, Drug Discovery, Marketing and Licensing Agreements, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Schering-Plough Corporation, Therapy, Treatment, Commonwealth Biotechnologies Inc. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
